AGMT Registry for Metastatic Colorectal Cancer Patients Receiving Third Line or Later Treatments
Led by Arbeitsgemeinschaft medikamentoese Tumortherapie · Updated on 2025-04-10
500
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Metastatic colorectal cancer mCRC is a serious condition with limited treatment options after multiple therapies. Researchers are gathering detailed information on patients with mCRC who have already had at least two lines of systemic therapy. This registry aims to understand how these patients are treated and how they fare over time, collecting data from multiple cancer centers in Austria to better evaluate treatment patterns and outcomes.
The study involves collecting existing medical data from patient charts, including treatment histories, test results, and imaging studies. Tumor tissue samples from deceased patients will be stored in a central biobank, and additional biological samples may be requested for specific research questions. No new diagnostic or treatment procedures are required beyond routine care. Data collection will continue until patient death or loss to follow-up.
Participants involvement includes providing consent for their routine medical data to be recorded in the registry. Researchers will monitor overall survival, progression-free survival, response rates, and potential predictive biomarkers over a period of up to 10 years. Patient confidentiality is maintained by assigning unique identifiers, and no extra visits or therapies are needed beyond usual care.
CONDITIONS
Brief Title
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Research Team
D
Daniela Wolkersdorfer, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients 18 years or older with a tissue-based diagnosis of metastatic colorectal cancer
Have received at least two prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (if RAS/BRAF wildtype), or anti-PD1 therapy (if MSI/MMRd)
Patients who received mFOLFOXIRI +/- anti-VEGF or anti-EGFR as first-line therapy or are ineligible for 5-FU, oxaliplatin, or irinotecan may be included after one line of therapy
Written consent obtained prior to data input
You will not qualify if you...
There are no specific exclusion criteria due to the non-interventional design of this registry
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to obtain written consent and confirm eligibility
Surveillance
Duration - Up to 10 years or until patient death or loss to follow-up
Participants who undergo routine care are observed. Data from medical charts, imaging, and biomaterials are collected without additional interventions.
Data collection occurs as part of routine care visits; no additional visits required for the registry
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Study of Arfolitixorin Compared to Standard Therapy with Leucovorin in Metastatic Colorectal Cancer Using 5-Fluorouracil-Based Chemotherapy Regimens
Evaluating Safety and Effectiveness of Intravenous HNF4b1 SrRNA for Adults With Metastatic Colorectal Cancer
AGMT Registry for Metastatic Colorectal Cancer Patients Receiving Third Line or Later Treatments
Phase 3 Study of Continuing Cetuximab With Chemotherapy Compared to Bevacizumab in Adults with RASBRAF Wild-Type Metastatic Colorectal Cancer After First-Line Progression
Study Evaluating the Therascreen KRAS RGQ PCR Kit to Detect KRAS G12C Mutation in Tumor Tissue of Patients with Metastatic Colorectal Cancer for Enrollment in Amgens Clinical Trial
Comparing Hydroxychloroquine with Methotrexate, Capecitabine, and Bevacizumab Versus Regorafenib for Advanced Colorectal Cancer with RAS Gene Mutations
Study of a New Diagnostic Test to Guide Drug Treatment for Metastatic Colorectal Cancer Patients
Observational Study on Fruquintinib Treatment in Adults with Metastatic Colorectal Cancer
Evaluating PDS01ADC Combined With Hepatic Artery Infusion Pump and Chemotherapy for Liver-Related Metastatic Cancers
Effects of Exercise Training on Quality of Life in Adults with Metastatic Colorectal Cancer Undergoing First-Line Chemotherapy
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancer.
Florian Huemer, Gudrun Piringer, Wolfgang Eisterer...